Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Gains from Investment Securities (2021 - 2025)

Senti Biosciences (SNTI) has 4 years of Gains from Investment Securities data on record, last reported at -$1.7 million in Q2 2025.

  • For Q2 2025, Gains from Investment Securities changed N/A year-over-year to -$1.7 million; the TTM value through Sep 2025 reached $6.6 million, up 360.39%, while the annual FY2024 figure was $6.4 million, 3324.5% up from the prior year.
  • Gains from Investment Securities reached -$1.7 million in Q2 2025 per SNTI's latest filing, down from $1.7 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $6.6 million in Q4 2024 and bottomed at -$8.9 million in Q2 2022.
  • Average Gains from Investment Securities over 4 years is -$111909.1, with a median of -$37000.0 recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: tumbled 391.67% in 2023, then skyrocketed 2576.27% in 2024.
  • A 4-year view of Gains from Investment Securities shows it stood at $100000.0 in 2022, then crashed by 362.0% to -$262000.0 in 2023, then soared by 2602.29% to $6.6 million in 2024, then tumbled by 126.13% to -$1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$1.7 million in Q2 2025, $1.7 million in Q1 2025, and $6.6 million in Q4 2024.